Resource Library
Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.
Related Resources
June 12, 2026
KT-621, an Oral, Once Daily STAT6 Degrader: Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Japanese Adults
Japanese Dermatological Association (JDA) 2026
Healthy Volunteers
Read More
June 11, 2026
Potent and Selective First-in-Class Oral IRF5 Degrader, KT-579, Inhibits Endosomal TLR-Induced Responses in SLE Derived PBMCs and Significantly Reduces Disease Activity in the MRL.lpr Mouse Lupus Model
Federation of Clinical Immunology Societies (FOCIS) 2026
Lupus
Read More
June 6, 2026
First-in-class Oral IRF5 Degrader, KT-579, Demonstrates Selective and Potent In Vitro and In Vivo Activity in Human Cellular Assays and Mouse Models of Lupus
European Alliance of Associations for Rheumatology (EULAR) 2026
Lupus
Read More
May 15, 2026
KT-621 Treatment Induces Rapid STAT6 Degradation and Modulation of Th2 Gene Transcripts in Atopic Dermatitis Lesional Skin
Society for Investigative Dermatology (SID) 2026 – Late Breaking Presentation
Atopic Dermatitis (AD)
Read More
May 15, 2026
Revolutionizing Immunology with Oral Medicines
American Thoracic Society (ATS) - Respiratory Innovation Summit 2026
Asthma
Atopic Dermatitis (AD)
Read More
May 5, 2026
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates Robust Anti-Inflammatory Activity and Disease Modulation in Preclinical In Vivo Models of Inflammatory Bowel Disease
Digestive Disease Week (DDW) 2026
March 28, 2026
Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results
American Academy of Dermatology (AAD) 2026 – Late Breaking Presentation
Atopic Dermatitis (AD)
Read More
January 13, 2026
Frontiers in Immunology: Targeted Degradation of MK2 is Insufficient to Block Inflammatory Cytokine Production in Human Cells Due to Cooperativity with MK3 and MK5
Yang, et al.
December 12, 2025
Toxicological Sciences: Developmental Toxicology Profile of the IRAK4 Degrader KT-474
Enerson, et al.
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in Rodent Models of Rheumatoid Arthritis
American College of Rheumatology (ACR) 2025